argenx SE - ESG Rating & Company Profile powered by AI
This webpage displays a free Sustainability analysis covering argenx SE. This report of argenx SE employs information from across the internet and also from available documents by argenx SE. The ESG assessment for argenx SE indicates its reporting of the United Nations Sustainable Development Goals.
argenx SE in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.2; made up of an environmental score of 2.3, social score of 5.7 and governance score of 6.9.
5.2
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 912 | Vivanza Biosciences Ltd | 5.3 | High |
| 912 | ValiRx PLC | 5.3 | High |
| 958 | argenx SE | 5.2 | High |
| 958 | Altimmune Inc | 5.2 | High |
| 958 | Agios Pharmaceuticals Inc | 5.2 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does argenx SE have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes argenx SE disclose current and historical energy intensity?
Sign up for free to unlockDoes argenx SE report the average age of the workforce?
Sign up for free to unlockDoes argenx SE reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes argenx SE disclose its ethnicity pay gap?
Sign up for free to unlockDoes argenx SE disclose cybersecurity risks?
Sign up for free to unlockDoes argenx SE offer flexible work?
Sign up for free to unlockDoes argenx SE have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes argenx SE disclose the number of employees in R&D functions?
Sign up for free to unlockDoes argenx SE conduct supply chain audits?
Sign up for free to unlockDoes argenx SE disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes argenx SE conduct 360 degree staff reviews?
Sign up for free to unlockDoes argenx SE disclose the individual responsible for D&I?
Sign up for free to unlockDoes argenx SE disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes argenx SE disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes argenx SE disclose water use targets?
Sign up for free to unlockDoes argenx SE have careers partnerships with academic institutions?
Sign up for free to unlockDid argenx SE have a product recall in the last two years?
Sign up for free to unlockDoes argenx SE disclose incidents of discrimination?
Sign up for free to unlockDoes argenx SE allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas argenx SE issued a profit warning in the past 24 months?
Sign up for free to unlockDoes argenx SE disclose parental leave metrics?
Sign up for free to unlockDoes argenx SE disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes argenx SE disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes argenx SE disclose the pay ratio of women to men?
Sign up for free to unlockDoes argenx SE support suppliers with sustainability related research and development?
Sign up for free to unlockDoes argenx SE disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes argenx SE reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs argenx SE involved in embryonic stem cell research?
Sign up for free to unlockDoes argenx SE disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes argenx SE disclose its waste policy?
Sign up for free to unlockDoes argenx SE report according to TCFD requirements?
Sign up for free to unlockDoes argenx SE disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes argenx SE disclose energy use targets?
Sign up for free to unlockDoes argenx SE disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes argenx SE have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for argenx SE
These potential risks are based on the size, segment and geographies of the company.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases. In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.